Stepping out as a global player, a restructured Takeda enrolls 20,000-plus in new dengue PhIII in a showdown with Sanofi
Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.